ASTARTZ
LIVE

Serial Number

79342589

Owner

NIHON MEDI-PHYSICS CO., LTD.

Attorney

Marina Dostal

Filing Date

Feb 25, 2022

Add to watchlist:

No watchlists yet
View on USPTO

ASTARTZ Trademark

Serial Number: 79342589 • Registration: 7141339

ASTARTZ is a trademark filed by NIHON MEDI-PHYSICS CO., LTD. on February 25, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services). The application is currently registered and active.

Owner Contact Info

NIHON MEDI-PHYSICS CO., LTD. (2 trademarks)

3-4-10, Shinsuna,
Tokyo 136-0075 , JP

Entity Type: 03

Trademark Details

Filing Date

February 25, 2022

Registration Date

August 22, 2023

Published for Opposition

June 6, 2023

Goods & Services

Industrial chemicals; chemical preparations for scientific purposes; diagnostic reagents for scientific or research use; chemicals for use in the manufacture of pharmaceuticals; chemicals for use in the manufacture of radiopharmaceuticals; radioactive elements for scientific purposes; isotopes for industrial purposes; peptide substrates for scientific purposes; peptide for use in the manufacture of pharmaceuticals; chelating agents for use in the manufacture of pharmaceuticals; polypeptides for scientific purposes; antibodies for scientific purposes, other than for medical or veterinary use; chelate compound; organic chelating agents; metal chelating agents

Research and development of medicines; testing, inspection or research services in the fields of pharmaceuticals; advisory, consultancy and providing information relating to testing, inspection or research services in the fields of pharmaceuticals; development of pharmaceuticals; advisory, consultancy and providing information relating to development of pharmaceuticals; conducting clinical trials for pharmaceuticals for others; advisory, consultancy and providing information relating to clinical trials for pharmaceuticals; research and development of radiopharmaceuticals; development of radiopharmaceuticals; advisory, consultancy and providing information relating to development of radiopharmaceuticals; research and development services relating to peptides; research and development services in the field of antibodies; research and development services relating to peptide labeling by radioactive substances; research and development services relating to antibody labeling by radioactive substances

Custom manufacture of pharmaceuticals; custom manufacture of investigational new drug; custom manufacture of radiopharmaceuticals; custom synthesis of labeled compound; custom manufacture of peptides; custom manufacture of antibodies; custom manufacture of proteins; custom protein modification; custom antibody modification; custom extraction of pharmaceuticals and veterinary preparations; custom synthesis and refining of pharmaceuticals and veterinary preparations; custom peptide synthesis services; custom synthesis and refining of pharmaceuticals consisting of antibodies; custom manufacture of pharmaceuticals consisting of antibodies; custom synthesis and refining of pharmaceuticals consisting of antibody fragments; custom manufacture of pharmaceuticals consisting of antibody fragments; custom synthesis and refining of pharmaceuticals consisting of antibody derivatives; custom manufacture of pharmaceuticals consisting of antibody derivatives; custom radioactive labeling of antibodies; custom radioactive labeling of antibody fragments; custom radioactive labeling of antibody derivatives; custom radioactive labeling of peptides

Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the diagnosis of cancer; chemical reagents for medical purposes; medical diagnostic reagents; radioactive substances for medical purposes; isotopes for medical purposes; radioisotope markers for therapeutic or diagnostic use; radioactive pharmaceutical preparations for in vivo diagnostics or therapeutic use; synthetic peptides for pharmaceutical purposes for the treatment of cancer; synthetic peptides for pharmaceutical purposes for the diagnosis of cancer; pharmaceuticals consisting of antibodies for the treatment of cancer; pharmaceuticals consisting of antibodies for the diagnosis of cancer; pharmaceuticals consisting of antibody fragments for the treatment of cancer; pharmaceuticals consisting of antibody fragments for the diagnosis of cancer; pharmaceuticals consisting of antibody derivatives for the treatment of cancer; pharmaceuticals consisting of antibody derivatives for the diagnosis of cancer; antibodies for medical purposes

Granting of licenses to others for the use of intellectual property; legal services, namely, exploitation of industrial property rights

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 17, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 17, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 17, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 17, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 17, 2025 COAR
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
Jun 18, 2024 NURC
CORRECTION UNDER SECTION 7 - PROCESSED
May 10, 2024 COC.
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
May 9, 2024 APRE
FINAL DECISION TRANSACTION PROCESSED BY IB
Dec 19, 2023 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Nov 27, 2023 FICS
FINAL DISPOSITION PROCESSED
Nov 27, 2023 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 22, 2023 FICR
TEAS SECTION 7 REQUEST RECEIVED
Aug 28, 2023 ES7R
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 22, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 22, 2023 R.PR
NOTIFICATION PROCESSED BY IB
Jun 6, 2023 GPNX
POST PUBLICATION AMENDMENT - ENTERED
Jun 6, 2023 CHPB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 6, 2023 NPUB
PUBLISHED FOR OPPOSITION
Jun 6, 2023 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
May 17, 2023 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
May 17, 2023 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 17, 2023 NONP
ASSIGNED TO PETITION STAFF
May 15, 2023 APET
APPROVED FOR PUB - PRINCIPAL REGISTER
May 1, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
May 1, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 1, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
May 1, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 1, 2023 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Apr 26, 2023 ZZZX
WITHDRAWN FROM PUB - MANAGING ATTORNEY REQUEST
Apr 25, 2023 PBMR
TEAS POST PUBLICATION AMENDMENT RECEIVED
Apr 22, 2023 EPPA
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 19, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 18, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 17, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 17, 2023 TROA
REFUSAL PROCESSED BY IB
Mar 6, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 15, 2023 RFCS
REFUSAL PROCESSED BY MPU
Feb 15, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 20, 2022 RFCR
NON-FINAL ACTION WRITTEN
Dec 19, 2022 CNRT
ASSIGNED TO EXAMINER
Dec 9, 2022 DOCK
NEW REPRESENTATIVE AT IB RECEIVED
Sep 30, 2022 NREP
APPLICATION FILING RECEIPT MAILED
Jun 28, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 23, 2022 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jun 22, 2022 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 16, 2022 REPR